Research location
Mons
Belgium
Advertisement
Research activity in Mons
BelgiumCureCurrent currently publishes aggregate city-level research activity for this location: 106 trials and 108 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Mons
106 linked trials · page 1 of 3A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation
RECRUITING
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24 · 1 site observation
RECRUITING
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · 2025-06-30 · 1 site observation
RECRUITING
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung CancerNCT06712316 · 2025-01-07 · 1 site observation
RECRUITING
Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung CancerNCT06896890 · 2023-06-23 · 1 site observation
RECRUITING
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · 2025-02-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT06034743 · 2023-11-22 · 1 site observation
COMPLETED
Insulin Delivery Using the DBLG1 Closed-loop on Glycemic Control and PROMs in Adults Living With Type 1 DiabetesNCT06154135 · 2022-12-30 · 1 site observation
UNKNOWN
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · 2022-11-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerNCT05005273 · 2022-10-03 · 1 site observation
COMPLETED
A Study of Oncobax®-AK in Patients With Advanced Solid TumorsNCT05865730 · 2022-10-01 · 1 site observation
UNKNOWN
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · 2022-07-22 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT05089734 · 2021-11-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsNCT05060432 · 2021-09-06 · 1 site observation
UNKNOWN
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)NCT04411641 · 2020-09-24 · 1 site observation
COMPLETED
Immunotherapy in Lung Cancer: Treatment After IO Cessation.NCT04465942 · 2020-06-26 · 1 site observation
UNKNOWN
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)NCT04410991 · 2020-06-11 · 1 site observation
COMPLETED
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart FailureNCT04157751 · 2020-05-18 · 1 site observation
COMPLETED
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)NCT04333147 · 2020-05-12 · 1 site observation
TERMINATED
The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMsNCT04414280 · 2020-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsNCT04134728 · 2019-10-31 · 1 site observation
COMPLETED
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerNCT03800134 · 2018-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Blood Pressure Control in ESH Excellence CentresNCT04295434 · 2018-10-01 · 1 site observation
UNKNOWN
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumNCT03761901 · 2018-09-21 · 1 site observation
COMPLETED
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerNCT03498716 · 2018-08-02 · 1 site observation
TERMINATED
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation
TERMINATED
Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective RegistryNCT03368820 · 2017-12-04 · 1 site observation
UNKNOWN
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationNCT03318939 · 2017-10-11 · 1 site observation
TERMINATED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)NCT02864992 · 2016-09-13 · 2 site observations
ACTIVE_NOT_RECRUITING
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung CancerNCT02566993 · 2016-08-30 · 1 site observation
COMPLETED
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateNCT02706873 · 2016-02-23 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Avelumab in First-line NSCLC (JAVELIN Lung 100)NCT02576574 · 2015-10-29 · 1 site observation
COMPLETED
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's DementiaNCT02569398 · 2015-10-29 · 1 site observation
TERMINATED
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusNCT02453711 · 2015-10-01 · 1 site observation
COMPLETED
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerNCT02370238 · 2015-07-29 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT02367781 · 2015-04-16 · 1 site observation
COMPLETED
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.NCT02337907 · 2015-01-21 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerNCT02352948 · 2015-01-13 · 1 site observation
COMPLETED
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung CancerNCT02289690 · 2014-10-13 · 1 site observation
COMPLETED
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical PracticeNCT02202837 · 2014-08-12 · 1 site observation
COMPLETED
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)NCT02038647 · 2014-05-12 · 1 site observation
COMPLETED
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) PatientsNCT02064868 · 2014-01-31 · 1 site observation
TERMINATED
Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenNCT02028364 · 2014-01-12 · 1 site observation
COMPLETED
A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)NCT01926886 · 2013-11-19 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) PatientsNCT01911325 · 2013-10-01 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.